Yamashita Kouhei, Nomoto Yuji, Hirose Tomoya, Yutani Akira, Okada Akira, Watanabe Nayu, Suzuki Ken, Senzaki Munenori, Kuroda Tomohiro
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Palliative Care Medicine, Niigata City General Hospital, Niigata, Japan.
JMIR Med Inform. 2024 Sep 13;12:e59858. doi: 10.2196/59858.
Hereditary angioedema (HAE), a rare genetic disease, induces acute attacks of swelling in various regions of the body. Its prevalence is estimated to be 1 in 50,000 people, with no reported bias among different ethnic groups. However, considering the estimated prevalence, the number of patients in Japan diagnosed with HAE remains approximately 1 in 250,000, which means that only 20% of potential HAE cases are identified.
This study aimed to develop an artificial intelligence (AI) model that can detect patients with suspected HAE using medical history data (medical claims, prescriptions, and electronic medical records [EMRs]) in the United States. We also aimed to validate the detection performance of the model for HAE cases using the Japanese dataset.
The HAE patient and control groups were identified using the US claims and EMR datasets. We analyzed the characteristics of the diagnostic history of patients with HAE and developed an AI model to predict the probability of HAE based on a generalized linear model and bootstrap method. The model was then applied to the EMR data of the Kyoto University Hospital to verify its applicability to the Japanese dataset.
Precision and sensitivity were measured to validate the model performance. Using the comprehensive US dataset, the precision score was 2% in the initial model development step. Our model can screen out suspected patients, where 1 in 50 of these patients have HAE. In addition, in the validation step with Japanese EMR data, the precision score was 23.6%, which exceeded our expectations. We achieved a sensitivity score of 61.5% for the US dataset and 37.6% for the validation exercise using data from a single Japanese hospital. Overall, our model could predict patients with typical HAE symptoms.
This study indicates that our AI model can detect HAE in patients with typical symptoms and is effective in Japanese data. However, further prospective clinical studies are required to investigate whether this model can be used to diagnose HAE.
遗传性血管性水肿(HAE)是一种罕见的遗传性疾病,可引发身体各部位的急性肿胀发作。据估计,其患病率为五万分之一,不同种族群体中均无报道显示存在偏差。然而,考虑到该估计患病率,日本确诊为HAE的患者数量仍约为二十五万分之一,这意味着仅有20%的潜在HAE病例被识别出来。
本研究旨在开发一种人工智能(AI)模型,该模型能够利用美国的病史数据(医疗理赔、处方和电子病历[EMR])来检测疑似HAE患者。我们还旨在使用日本数据集验证该模型对HAE病例的检测性能。
使用美国的理赔和EMR数据集确定HAE患者组和对照组。我们分析了HAE患者诊断史的特征,并基于广义线性模型和自助法开发了一个AI模型来预测HAE的概率。然后将该模型应用于京都大学医院的EMR数据,以验证其对日本数据集的适用性。
通过测量精度和敏感性来验证模型性能。在初始模型开发步骤中,使用全面的美国数据集,精度得分是2%。我们的模型可以筛选出疑似患者,其中每50名此类患者中有1名患有HAE。此外,在使用日本EMR数据的验证步骤中,精度得分是23.6%,超出了我们的预期。对于美国数据集,我们的敏感性得分为61.5%,对于使用一家日本医院数据的验证试验,敏感性得分为37.6%。总体而言,我们的模型可以预测具有典型HAE症状的患者。
本研究表明,我们的AI模型能够检测出具有典型症状的HAE患者,并且在日本数据中有效。然而,需要进一步的前瞻性临床研究来调查该模型是否可用于诊断HAE。